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This study investigated the active principles, hypoglycemic activity and potential
mechanisms of the flavonoid rich extract from Sophora tonkinensis Gagnep. (ST-EtOAc)
in KK-Ay diabetic mice. An off-line semipreparative liquid chromatography-nuclear
magnetic resonance (LC-NMR) and liquid chromatography-ultraviolet-electrospray
ionization mass spectrometry (LC-UV–ESIMS) protocol was performed to determine 13
flavonoids from ST-EtOAc. ST-EtOAc administrated orally to the KK-Ay mice significantly
increased their sensibility to insulin, reduced fasting blood-glucose levels and blood lipid
indexes such as triglyceride and cholesterol. Moreover, ST-EtOAc exhibited a strong
effect of stimulation on glucose transporter 4 (GLUT4) translocation by 2.7-fold in L6
cells. However, the selective AMP-activated protein kinase (AMPK) inhibitor compound
C can completely inhibit the activation of the AMPK pathway and prevent the GLUT4
translocation caused by ST-EtOAc. In vivo, phosphorylation of the AMPK expression
in the liver and skeletal muscle was measured. The results showed phosphorylation
of the AMPK had been improved and GLUT4 expression had been also enhanced. In
this paper, we conclude that, ST-EtOAc seems to have potential beneficial effects on
the treatment of type 2 diabetes mellitus with the probable mechanism of stimulating
GLUT4 translocation modulated by the AMPK pathway.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM), a metabolic disorder of the endocrine system characterized
by abnormal glucose and lipid metabolism, is caused by insulin resistance and relative insulin
deficiency (Shulman, 2000). Because insulin resistance is the main metabolic abnormality of
T2DM, there has been considerable interest in insulin-sensitizing agents for the treatment of this
disease (Moller, 2001; Ju et al., 2014). One of the most appealing targets for drug development is the
insulin-responsive glucose transporter 4 (GLUT4), which is vital to glucose homeostasis (Bryant
et al., 2002). Increasing evidence suggests that enhanced translocation of GLUT4 can improve
insulin resistance of T2DM. Therefore, this protein may lead to the discovery of the next generation
of anti-diabetic drugs (Zhang et al., 2007; Tsuchiya et al., 2015).
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Many traditional Chinese medicines (TCMs), which contain
many active compounds targeting GLUT4 proteins, have revealed
beneficial hypoglycemic effects in vitro and in vivo, such as Coptis
chinensis (Turner et al., 2008), Momordica charantia (Tan et al.,
2008), and Gardenia jasminoides (Zhang et al., 2006), etc. In
order to identify potential hypoglycemic agents to fight T2DM,
we developed a L6 cell-based GLUT4 translocation system with
co-expressing recombinant GLUT4 and insulin regulation of
aminopeptidase (IRAP) using a confocal imaging technique to
screen the extracts or fractions from natural products (Wang
et al., 2014; Yang X.Z. et al., 2014; Yang et al., 2015). During
the screening of a TCMs extract library (800 biotas) on GLUT4
translocation, we have found that a flavonoid rich extract
of Sophora tonkinensis Gagnep. (ST-EtOAc) had a potentially
beneficial effect on GLUT4 translocation.
Sophora tonkinensis Gagnep. belongs to the leguminous
family, and has been widely used as a traditional medicine
in China (Tan et al., 2009). Clinically, it is mainly used to
treat acute and chronic pharyngitis, tonsillitis, and chronic
hepatitis (Sheng et al., 2010). However, the hypoglycemic effect of
S. tonkinensis Gagnep. has not been reported until now. The aim
of this investigation was to determine the active principles, and
evaluate the potential hypoglycemic effects of ST-EtOAc in vitro
and in vivo, and therefore elucidate its probable hypoglycemic
mechanism.
MATERIALS AND METHODS
Instruments and Reagents
Liquid chromatography-photo-diode array-electrospray
ionization mass spectrometry (LC-PDA-ESIMS) data were
recorded on a Waters ACQUITY SQD MS system (Waters,
Milford, MA, USA) connected to a Waters 1525 high
performance liquid chromatography (HPLC) with a 2998
Photodiode Array Detector (Waters, Milford, MA, USA) and a
Waters SunfireTM C18 column (5 µm, 4.6 × 150 mm) (Waters,
Ireland). The nuclear magnetic resonance (NMR) spectra were
recorded in dimethyl sulfoxide (DMSO)-d6 on an spectrometer
(AVANCE III 500 MHz) equipped with 1.4 mm heavy wall Micro
NMR tubes (NORELL, Landisville, NJ, USA). All the other
analytical-reagent grade chemicals were used with no further
purification, and HPLC-grade solvents were obtained from
Merck Chemical Company (Darmstadt, Germany). The NMR
(high-Resolution solution: MeOH-d4 or DMSO-d6) spectra
were kept a record in on an AVANCE III 500 MHz spectrometer
equipped with Micro NMR tubes (1.4 mm). Typically, 1H spectra
and 1H-1H COSY spectra were separated obtained at the scan
range of 32–128 and 4–32. The heteronuclear multiple bond
correlation (HMBC) and the heteronuclear single quantum
coherence (HSQC) spectra were recorded at the scan range of
16–96.
LC–PDA–ESIMS Method
Analysis was performed on a C18 column (Waters Sunfire, 5 µm,
4.6 × 150 mm). 0.1% formic acid added in Water (A) and
acetonitrile (B) was used as mobile phases. The gradient elution
was used for analysis and the program was as follows: 0–20 min,
10–100% B; 20–24 min, 100% B. The flow rate of the analysis was
1.0 mL/min. UV-Vis spectra were obtained with the wavelength
range of 200–500 nm with 10 scans per second. The splitted
eluent was at a ratio of 1:5 before the mass spectrometer. Both
positive and negative ion modes were used for ESIMS recording.
The capillary voltage was 4000 V, the capillary exit voltage was
140.0 V, and the skimmer voltage was 40 V. The nebulizer gas
pressure was set to 40 psi, the dry gas flow to 10.0 L/min and
the dry temperature to 320◦C. Mass range was set from 120 to
1500 m/z. Data acquisition and processing were achieved with
MassLynxTM 4.0 software (Waters, Milford, MA, USA).
Plant Material and Preparation of
ST-EtOAc
The roots of S. tonkinensis Gagnep. were collected from
Jingxi county, Guangxi Zhuang Autonomous Region, China in
June 2013. And it was identified by Professor Jingquan Yuan
(Guangxi Medicinal Botanical Garden, Nanning, China). The
plant voucher specimen was preserved as No. SC0060 and
deposited in College of Pharmacy, South-Central University
for Nationalities. Air-dried roots of S. tonkinensis Gagnep.
(500 g) were smashed and then extracted sequentially at room
temperature with n-hexane (4× 2.0 L, 3 h each), followed by ethyl
acetate (4 × 2.0 L, 3 h each) and methanol (4 × 2.0 L, 3 h each).
The solvents were vacuum evaporated to yield n-hexane extract
(4.9 g), ethyl acetate extract (ST-EtOAc, 36.8 g), and methanol
extract (58.7 g), respectively.
Chemical Characterization
Separation of ST-EtOAc was carried by the procedures as
follows: 0.5 g of ST-EtOAc was dissolved in 2.0 mL of DMSO
so that a concentration of ST-EtOAc was 250 mg/mL, and
then the solution was filtered. With the same solvent system
to that of LC–PDA–ESIMS, the optimized gradient program
used as follows: 0–25 min, 15–100% B; 25–30 min, 100% B.
The flow rate was set at 5.0 mL/min and the 200 µL injected
volume was setup. Ten injections were carried out, and 13 peak-
based fractions were collected manually. And combined the
corresponding fractions. Final purification were performed as
follows: peaks 1–6, 10, 12, and 13 were filtered by a Sephadex
LH-20 column (400 mm × 10 mm, MeOH containing 0.1%
formic acid) to yield pure compounds 1 (2.9 mg), 2 (2.1 mg), 3
(3.8 mg), 4 (3.5 mg), 5 (1.9 mg), 6 (23.3 mg), 10 (37.6 mg), 12
(3.2 mg), and 13 (7.1 mg). Peak 7 was purified by preparative
thin layer chromatography (TLC) (hexane:acetone:formic acid—
100:10:0.5) to yield compound 7 (1.2 mg). Peak 8 was purified
by preparative TLC (hexane:acetone:formic acid—100:10:0.4)
to give compound 8 (1.8 mg). Peak 9 was purified by
preparative TLC (hexane:acetone:formic acid—100:8:0.4) to give
compound 9 (2.8 mg). Peak 11 was purified by preparative
TLC (hexane:acetone:formic acid—100:8:0.4) to give compound
11 (1.4 mg). Compounds 1–13 with amounts 0.8–3.0 mg were
dissolved in DMSO-d6 or MeOH-d4 for NMR tests on a
spectrometer (AVANCE III 500 MHz) which was equipped with
1.4 mm heavy wall Micro NMR tubes.
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Plasmid and Cell Line Construction
pIRAP-mOrange cDNAs, presented by Professor Xu Tao
(Institute of Biophysics, Chinese Academy of Sciences), were
inserted into the pQCXIP plasmid. The retrovirus was prepared
by transfecting pQCXIP-IRAP-mOrange, vesicular stomatitis
virus glycoprotein (VSVG), and PHIT60 with a ratio of 2:1:1
by lipofectamine 2000 into PLATELET cells, collecting the
cultural supernatant after 48 h, and concentrating the viruses by
supercentrifuge (50,000 g, 30 min). L6 cells at the exponential
growth phase were infected with fresh prepared viruses. The
polybrene (Millipore, 8 µg/mL) was used to facilitate the
infection efficiency. The red fluorescence cells were isolated
by fluorescence activated cell sorter (FACS) and single cell
was seeded into 96 well-plates. Finally the single clone, which
had the highest increase in red fluorescence intensity following
stimulation with insulin (100 nM), was selected.
IRAP Translocation Assay
GLUT4 has mainly been recruited to the plasma membrane (PM)
throughout to the GLUTs storage vesicles (GSV). Three main
proteins stored in GSV are GLUT4, IRAP, and Sortilin (Shi and
Kandror, 2005). Many researches reported that IRAP and GLUT4
displayed a strong colocalization (Rubin and Bogan, 2009; Kumar
et al., 2010). Thus, detecting the IRAP can indirectly reflect the
situation of GLUT4. The methodology validation could be found
in S1 in the Supplementary Material.
L6 cells which stably express IRAP-mOrange were cultured
in minimum essential media (MEM)-α supplemented with
10% fetal bovine serum (FBS) and 1% antibiotics (100 U/mL
penicillin and 100 µg/mL streptomycin) at 37 C in 5% CO2. L6
IRAP-mOrange was seeded in 48 well plates, and incubated until
100% confluence and then starved in serum-free MEM-α for 2 h.
Afterward, L6 cells were treated with samples and other agents.
Compound C {6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-
4-ylpyrazolo[1,5-a] pyrimidine, commonly used as an inhibitor
of AMP-activated protein kinase (AMPK)} and Wortmannin
{(1S,6bR,9aS,11R,11bR)-11-(acetyloxy)-1, 6b, 7, 8, 9a, 10,11,11b-
octahydro-1-(methoxy-methyl)-9a,11b-dimethyl-(3H-Furo[4,3,
2-de]indeno[4,5-h]-2-benzopyran-3,6,9-trione, commonly used
as a phosphatidylinositol 3-kinase (PI3K) inhibitor)} was used
to investigate the mechanism. The cells photos were taken with
a laser-scanning confocal microscope LSM 510 (Carl Zeiss, Jena,
Germany) to supervise the IRAP-mOrange translocation. And
the images were captured with 555 nm excitation laser every 10 s
in first 5 min and then every 5 min in later 25 min.
Determination of Glucose Uptake in L6
Myocytes
MEM-α, FBS, and antibiotics (100 U/mL penicillin and
100 µg/mL streptomycin) were purchased from Hyclone, USA.
L6 Cells were maintained in MEM-α and used for experiment
described previously (Al-Maharik and Botting, 2008; Li et al.,
2008; Lee et al., 2015). A cell-based 2-[N-(7-nitrobenz-2-oxa-1,3-
diaxol-4-yl)amino]-2-deoxyglucose (2-NBDG) Glucose Uptake
Assay Kit (Cayman Chemical, USA) was used to measure
the effects of ST-EtOAc in promoting the glucose uptake
on L6 cells. L6 cells were seeded in a 96-well plate with
1 × 104–5 × 104 cells/well in 100 µL MEM-α medium.
After 12 h incubation, the myotubes were treated with
different concentration of ST-EtOAc, 10 µM compound C (an
AMPK inhibitor) and 5-aminoimidazole-4-carboxamide 1-β-D-
ribofuranoside (AICAR) (an AMPK agonist) or normal control
in 100 µL (150 µg/mL 2-NBDG) glucose-free MEM-α medium.
After 24 h incubation, the glucose uptake of L6 cells was
measured as the method described by the Cayman assay kit.
Preparation of Protein in L6 Myotubes
and Western Blotting
L6 cells (5 × 105 cells) were subcultured into 60 mm dishes and
cultured for 7 days to form myotubes in 3 mL of MEM-α with 2%
FBS. After incubation, the L6 myotubes were treated with AICAR
(1 mM), compound C (40 µM), ST-EtOAc, or vehicle (0.1%
DMSO) for 60 min. The total protein samples were extracted
from L6 myotubes, and western blotting for AMPK and phospho-
AMPK was conducted as described previously (Yang J. et al.,
2014; Yang et al., 2015). The antibodies specific for AMPKα (No.
2532), p-AMPKα (Thr172; No. 4188) were purchased from Cell
Signaling Technology (Danvers, USA).
Animals and Treatments
All experimental procedures were reviewed and approved by
the Animal Ethical Committee of the Institute of Health and
Epidemic Prevention (Wuhan, China; the protocol number
2015-SCUEC-AEC-0026), and animal care was conducted in
accordance with institutional guidelines. The KK-Ay mice
(n = 65, 8 weeks old, male) and C57BL/6J mice (n = 10,
8 weeks old, male) were purchased from the Beijing HFK
Bioscience Co, Ltd (SCXK 2009-0015). All mice were individually
housed in laminar flow cabinets under specific pathogen-free
conditions. The KK-Ay mice were given a high-fat diet purchased
from Medicience Co., Ltd., Yangzhou, China. The composition
of the diet was as follows: protein, 225 g/kg; fat, 200 g/kg;
carbohydrate substances, 450 g/kg; cholesterol, 12.5 g/kg; sodium
cholate, 5 g/kg; energy, 4500 kcal/kg. After consecutive 4 weeks
feeding, the average weight of KK-Ay reached 43 g and the
fasted blood glucose levels of the mice were tested. The fasted
blood glucose levels ≥11.1 mmol/L were classified as T2DM,
and there were 50 mice up to the standard. These T2DM mice
were divided randomly into five groups: vehicle group (group
I, saline treatment, n = 10), ST-EtOAc treatment (group II–IV,
dose of 60, 120, 240 mg/kg/day, n = 10/group), and Metformin
treatment group (group V, 200 mg/kg/day, n= 10), the C57BL/6J
mice (n = 10) were given standard laboratory diet (Beijing HFK
Bioscience Co., Ltd) and as a normal control with saline. KK-Ay
mice were feed with high-fat diets and C57BL/6J mice were feed
with standard laboratory diet in the whole experimental period.
All the groups were intragastric administration one time every
day for four consecutive weeks.
The body weights were weekly recorded. Fasted blood glucose
levels were measured weekly by an OneTouch blood glucose
meter (Lifescan Inc., Wayne, USA). An oral glucose tolerance
test (OGTT) was performed in mice after 12 h fasting at the
26th day of treatment. Blood glucose taken from the tail tip at 0,
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30, 60, and 120 min after glucose administration was measured
using a blood glucose meter (OneTouch Ultra R©, Lifescan Inc.,
Wayne, USA). The glucose load was 2.0 g/kg orally. At the end
of the experiment, the mice were fasted for 12 h. Blood samples
were collected by retro-orbital sinus puncture using capillary
tubes under diethyl ether anesthesia. Then, the blood samples
were centrifuging at 3000 rpm for continues 15 min so that the
serum of each sample was obtained. At the same time, the mice
were euthanized by cervical dislocation. And the livers, skeletal
muscles, and other tissues were harvested. Parts of livers and
pancreas were immediately stored in liquid nitrogen tank, and
the rest parts were stored in 10% neutral buffered formalin to be
fixed.
Liver and Pancreas Histological Analysis
Livers and pancreas fixed in formalin were embedded in
paraffin, and then they were cut into 5 µm-thick sections and
stained with standard hematoxylin–eosin (HE). The stained
tissues were prepared for histopathological examinations, and
pathological changes of the lesion and its vicinity in liver
and pancreas were observed and photographed through an
optical microscope photographed (200×). The average islet
size (in µm2), was determined with software (program Stereo
Investigator, Williston, VT, USA).
Biochemical Analyses of Serum and
Tissues
The serum levels of insulin, total cholesterol (TC), triglycerides
(TG), low density lipoprotein cholesterol (LDL-C), and high
density lipoprotein cholesterol (HDL-C) were determined by
automatic biochemical analyzer (Hitachi 7180+ISE, Tokyo,
Japan). Free fatty acid (FFA) was determined by corresponding
assay kits (Jiancheng Bioengineering Institute, Nanjing, China).
The tissue TC, TG, and FFA in mice were determined
according to the method described previously (Lee et al.,
2006).
Tissue Extracts and Western Blotting
The total protein was extracted from skeletal muscle and liver
according to the methods described previously (Yang et al., 2015).
And the supernatant protein concentration was determined with
bicinchoninic acid (BCA) assay kit (Abgent, San Diego, USA).
An equivalent amount of samples were mounted on 10% sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. The
protein transferred electrophoretically to polyvinylidene fluoride
membrane (Pall Corporation, Washington, USA) and incubated
overnight at 4◦C with antibodies specific for GLUT4 (No.
2213), AMPKα (No. 2532), p-AMPKα (Thr172; No. 4188;
Cell Signaling Technology, Danvers, USA). The membranes
were washed three times (10 min/wash) in tris buffered saline
tween (TBST). Immune complexes were incubated with a
peroxidase-conjugated antibody for 1 h. The blots were incubated
in enhanced chemiluminescence kits (Amersham-Pharmacia,
Piscataway, NJ, USA). And the immunoreactive signals were
imaged and quantified with the Gel Image system (Aplegen Inc.,
Pleasanton, USA).
Acute Toxicity Study
Kung Ming (KM) mice were derived in 1944 from a pair of
Swiss mice that had been introduced from Hoﬄine Institution
of Hindustan into Kunming of China (Shang et al., 2009).
Kunming mice are the most commonly used outbred mouse
line in China. This type of mice shows strong disease resistance
and adaptability, high breeding coefficient and survival rate
(Shang et al., 2009). So, KM mice have been widely utilized
in pharmacological, toxicological, medicinal, and biological
research and testing.
KM mice [No. SCXK (E) 2008-0005] weighing between
18 and 22 g were served as acute toxicity test. The animals
were housed environmentally controlled conditions at 25◦C,
60% relative humidity, where 12 h dark–light cycles were
maintained with food and water. In the main study, the drug
(ST-EtOAc dissolved in saline) was administered orally given to
10 male mice and 10 female mice at doses of a single dose of
(6500 mg/kg/day). KM mice were observed for clinical symptoms
for 15 days. At the end of the experiments, all the animals were
euthanized followed and gross pathological examinations were
undertaken.
Statistical Analysis
Data was shown as means ± standard error of the mean.
One-way analysis of variance (ANOVA) was used for multiple
group comparisons by Tukey’s post hoc test using GraphPad
Prism 5.0 software package. P-values <0.05 were considered
significant.
RESULTS
Chemical Characterization of ST-EtOAc
A LC–PDA–ESIMS experiment was carried out for chemical
profiling of ST-EtOAc based on the standard operation procedure
shown in Section “LC–PDA–ESIMS Method” (Figure 1A). The
semipreparative HPLC chromatogram was used for large scale
preparative isolation of target compounds with the optimized
gradient conditions (Figure 1B). Thirteen peaks were collected
and continue to further purified with Sephadex LH-20 column
and preparative TLC to acquire 13 compounds for further 1D and
2D NMR spectroscopic analysis. The two major principles were
determined as maackiain (6; Lee et al., 2015) and sophoranone
(10; Li et al., 2008). The remaining compounds (Figure 1C)
were identified as genistin (1; Al-Maharik and Botting, 2008),
trifolirhizin (2; Yang X.Z. et al., 2014), ononin (3; Yang X.Z.
et al., 2014), trifolirhizin 6′-monoacetate (4; Yang X.Z. et al.,
2014), quercetin (5; Yi et al., 2002), lespeflorin B4 (7; Mori-
Hongo et al., 2009), dehydrolupinifolinol (8; Sutthivaiyakit
et al., 2009), glabrol (9; Cho et al., 2012), euchrenone a2 (11;
Mizuno et al., 1988), 6,8-diprenylkaempferol (12; Meragelman
et al., 2001), and sophoranochromene (13; Li et al., 2008) by
comparison with their mass spectrum (MS), UV, and NMR
spectra with published reference data. Spectroscopic data of
compounds 1–13 could be found in S2 in Supplementary
Material.
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FIGURE 1 | (A) The liquid chromatography-photo-diode array-electrospray ionization mass spectrometry (LC-PDA-ESIMS) analysis of ST-EtOAc is shown at 280 nm
with peak labeling corresponding to compounds 1–13. (B) The optimized semipreparative high performance liquid chromatography (HPLC) separation of the
ST-EtOAc (50 mg in 200 µL dimethyl sulfoxide (DMSO)) is shown at 280 nm with peaks 1–13 collected for microprobe nuclear magnetic resonance (NMR) and
further purified if required. (C) Structures of flavonoids from ST-EtOAc.
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FIGURE 2 | ST-EtOAc stimulated IRAP tracking in L6 cell. (A) L6 cells were infected with pIRAP-mOrange in order to detect externalized IRAP by confocal
microscopy. Confocal images in L6 cells incubated in the absence (basal) or presence of ST-EtOAc for 30 min. (B,C) Data represent the fold increase in fluorescence
induced by ST-EtOAc with inhibitors between 0 and 30 min. ∗∗∗P ≤ 0.001, ∗∗P ≤ 0.01, ∗P ≤ 0.05 compared to ST-EtOAc+Compound C group. (D) The effects of
ST-EtOAc on stimulation of glucose uptake in L6 cells. ++P ≤ 0.01, compared to Normal control group. ∗∗∗P ≤ 0.001, ∗∗P ≤ 0.01, ∗P ≤ 0.05 compared to Normal
control group. (E) The effect of ST-EtOAc on AMPK phosphorylation in L6 cells. (F) Compound C inhibits the effects of ST-EtOAc on AMPK phosphorylation.
∗∗∗P ≤ 0.001, compared to ST-EtOAc group.
Effects of ST-EtOAc on GLUT4
Translocation, Glucose Uptake, AMPK
Phosphorylation in L6 Myotubes
As shown in Figure 2A, L6 cells stably expressing IRAP-
mOrange were highly ST-EtOAc-responsive in terms of ST-
EtOAc regulated IRAP translocation, and the effect on the
translocation of IRAP was obviously enhanced by adding
of ST-EtOAc. The results of mechanism study (Figure 2B)
displayed that the translocation of IRAP to PM caused by ST-
EtOAc stimulation was mainly inhibited by the prior adding of
compound C (an inhibitor of AMPK). However, the addition
of Wortmannin had no effect on the IRAP trafficking response
(Figure 2C), suggesting that ST-EtOAc enhanced GLUT4
translocation by specifically targeting AMPK pathway. In the
later study, the effect of ST-EtOAc stimulating glucose uptake
in L6 cells was also tested. The promotion of glucose uptake
was significantly inhibited by treatment with compound C.
And comparing with the vehicle control, L6 cells were treated
with different concentration of ST-EtOAc showing significantly
effects on enhancing glucose uptake (Figure 2D). We performed
western blotting assay using compound C and AICAR (an
agonist of AMPK), to determine the regulatory mechanism by
which ST-EtOAc induced the glucose uptake in L6 myotubes.
As shown in Figures 2E,F, after adding of ST-EtOAc, the
AMPK phosphorylation were increased in L6 cells compared with
normal control and presented a dose-depending effect. However,
the effects of AMPK phosphorylation caused by ST-EtOAc were
repressed when adding compound C. So we can infer that glucose
uptake enhancing in L6 cells by ST-EtOAc was modulated by
activation of AMPK pathway.
Effects of ST-EtOAc on Body Weight,
Fasted Blood Glucose Levels, Oral
Glucose Tolerance
During the experiment, body weights of all groups of mice
were monitored weekly (Figure 3). As shown in Figure 3A, the
body weights of metformin and ST-EtOAc treated groups were
reduced up in 4 weeks. Adversely, the vehicle control group had
a little weight gain, compared to the initial weight. However,
there were no significant differences in food intake between the
vehicle group and ST-EtOAc groups during the 28 days treatment
(Figure 3B). At the same time, we administered ST-EtOAc orally
to KK-Ay mice to measure its glucose-lowering effect in vivo. As
shown in Figure 3C, the treated mice had a steady and marked
reduction in blood glucose level compared with vehicle group,
whereas the control mice had no significant changes in the serum
glucose level.
OGTT was also improved significantly, as evidenced by lower
glucose levels at all time points after glucose loading. An OGTT
was performed in mice at the 26th day of ST-EtOAc treatment.
As shown in Figure 3D, an obvious improvement in OGTT was
observed in metformin and ST-EtOAc groups. The data of Body
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FIGURE 3 | Effects of ST-EtOAc on body weight, serum glucose level, OGTT, and food intake. (A) The effects of ST-EtOAc on body weight. (B) The effects
of ST-EtOAc on food intake. (C) The effects of ST-EtOAc on OGTT. (D) The effects of ST-EtOAc on fasted blood glucose level. +++P ≤ 0.001, compared to normal
control; ∗∗∗P ≤ 0.001, ∗∗P ≤ 0.01, ∗P ≤ 0.05, compared to T2DM mice treated with vehicle.
FIGURE 4 | (A–E) Effects of ST-EtOAc on TC, TG, FFA, HDL-C, and LDL-C levels in the serum. (F) The effects of ST-EtOAc on serum insulin concentration.
+++P ≤ 0.001, ++P ≤ 0.01, compared to normal control; ∗P ≤ 0.01, ∗∗P ≤ 0.05, ∗∗∗P ≤ 0.001, compared to T2DM mice treated with vehicle.
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FIGURE 5 | Tissue lipid content after 4 weeks treatment. TC (A), TG (B), and FFA (C) levels in mice liver tissue; TC (D), TG (E), and FFA (F) levels in mice
skeletal muscle tissue. +++P ≤ 0.001, ++P ≤ 0.01, compared to normal control; ∗∗∗P ≤ 0.001, ∗∗P ≤ 0.01, ∗P ≤ 0.05, compared to T2DM mice treated with
vehicle.
Weight, Fasted Blood Glucose Levels and Oral Glucose Tolerance
could be found in S3 in Supplementary Material.
Effects of ST-EtOAc on Glucolipid
Metabolism
We have examined the effects of ST-EtOAc on serum lipid
parameters and adipose accumulation in liver and skeletal muscle
in all mice. It was shown that ST-EtOAc significantly reduced
the serum TC, TG, FFA, and LDL-C, and increased the serum
HDL-C level in Figures 4A–E. Serum insulin was substantially
reduced in the ST-EtOAc treated groups. The results showed
that after treating, the insulin levels in treated groups were
reduced significantly, illustrating ST-EtOAc can relieve the IR
in KK-Ay mice (Figure 4F). TC, TG, FFA in skeletal muscle
and liver had been reduced significantly throughout 4 weeks
treatment by ST-EtOAc (Figure 5). The data of related index of
Glucolipid Metabolism in KK-Ay mice could be found in S3 in
Supplementary Material.
Mouse Pancreas and Liver Histological
Changes
In the study, we performed histological examinations to observe
whether ST-EtOAc have the capacity of protecting pancreas
in KK-Ay mice. The results showed that ST-EtOAc could
alleviate the abnormity caused by diabetes in KK-Ay mice via
a dose-dependent manner (Figure 6). In the vehicle group, the
hepatic steatosis and empty lipid vacuoles appeared obviously
in liver, however, after the treatment of ST-EtOAc for 4
weeks, the degree of hepatic steatosis and empty lipid vacuoles
was reversed, especially in the 240 mg/kg ST-EtOAc group
(Figure 7).
Western Blot Analysis on Tissues
In this study, we have demonstrated the possible AMPK-
GLUT4 pathway of the effects of ST-EtOAc in L6 cells. In
vivo, additionally, we examined the expression of p-AMPK and
GLUT4 in the skeletal muscles. As expected, the results showed
that the expression of GLUT4 and p-AMPK in skeletal muscles of
T2DM mice had been improved. Especially, the 120 mg/kg/day
group revealed the similar effects to the 240 mg/kg/day group in
enhancing the phosphorylation of AMPK after 28 days treatment
(Figure 8A).
At the same time, we have examined the phosphorylation of
AMPK in liver by western blotting. As shown in Figure 8B, the
levels of phosphorylated AMPK significantly were increased in
the livers in KK-Ay mice treated with ST-EtOAc. These findings
suggested that ST-EtOAc may active the AMPK pathway to
attenuate lipogenesis in hepatocytes.
Results of Acute Toxicity Study
During the acute toxicity study, 15 days observation period
performed on ST-EtOAc treated KM mice have not produced
mortality, abnormal clinical features, body weight disorders
and food consumption, and toxicological changes in clinical
biochemistry and hematology as well as other toxic signs (data
has not been shown). The acute oral toxicity results showed that
at the dose of 6500 mg/kg/day, ST-EtOAc concentrate is unlikely
to be poisonous in KM mice.
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FIGURE 6 | Effectsof ST-EtOAc on morphological features of mice
pancreas. Optic microscopy: HE (×200). The arrows represent the islets of
the mice pancreas. (A) Normal control. (B) KK-Ay mice treated with vehicle.
(C) KK-Ay mice treated with metformin (200 mg/kg). (D) KK-Ay mice treated
with ST-EtOAc (60 mg/kg). (E) KK-Ay mice treated with ST-EtOAc
(120 mg/kg). (F) KK-Ay mice treated with ST-EtOAc (240 mg/kg).
(G) Quantitative analysis of islet area. +++P ≤ 0.001, compared to normal
control; ∗∗∗P ≤ 0.001, ∗∗P ≤ 0.01, ∗P ≤ 0.05, compared to T2DM mice
treated with vehicle.
FIGURE 7 | Effects of ST-EtOAc on morphological features of mice
livers. Optic microscopy: HE (×200). The arrows represent the lipidosis in the
mice livers. (A) Normal control. (B) KK-Ay mice treated with vehicle. (C) KK-Ay
mice treated with metformin (200 mg/kg). (D) KK-Ay mice treated with
ST-EtOAc (60 mg/kg). (E) KK-Ay mice treated with ST-EtOAc (120 mg/kg).
(F) KK-Ay mice treated with ST-EtOAc (240 mg/kg).
DISCUSSION
Many TCMs have worked effectively served as adjuvants used
to improve diabetic syndromes in combination with routine
hypoglycemic drugs (Xie et al., 2011). Additionally, many TCMs,
such as Swertia macrosperma (Wang et al., 2013), M. charantia
(Tan et al., 2008), G. jasminoides (Zhang et al., 2006), and
C. chinensis (Turner et al., 2008) etc., have been reported as
having beneficial hypoglycemic effects in vitro and in vivo.
Although many natural products have been used as hypoglycemic
agents, many of them have not been studied deeply.
In order to look for potential hypoglycemic agents in natural
products, we established a cell-based GLUT4 translocation assay
using stable L6 cells expressing pIRAP-mOrange cDNAs. Our
goal was to identify potential hypoglycemic plant extracts,
fractions, and their isolated compounds by evaluating their
effects on GLUT4 translocation. As we found, the plant extract
ST-EtOAc displayed a strong effect on GLUT4 translocation
by 2.7-fold in L6 cells. Based on the in vitro findings,
we speculated that ST-EtOAc may have the hypoglycemic
potency in vivo. And as we predicted, the in vivo data clearly
validated the hypoglycemic activity of ST-EtOAc, including
the ameliorative hyperglycemia and hyperinsulinemia in KK-
Ay mice. The OGTT further indicated that hyperglycemia and
hyperinsulinemia were considerably improved throughout ST-
EtOAc treatment.
GLUT4 is the most important glucose transporter in skeletal
muscle glucose metabolism (Huang and Czech, 2007), and it also
plays an important role in insulin resistant, is the remarkable
character in T2DM (Okamura et al., 2014). Promoting the
GLUT4 translocation onto PM or expression in cells will
relieve the T2DM. In this study, we found that ST-EtOAc
had a strong stimulation on GLUT4 transportation onto PM.
The expression of GLUT4 in skeletal muscle in KK-Ay mice
treated with ST-EtOAc was elevated significantly, and presented
a dose resistance according to the relationship. To evaluate
the effects of ST-EtOAc on improving IR, indicators related to
glycolipid metabolism in serum and tissues were examined. As
the results shown in Figures 3–5, after 4 weeks of treatment
with ST-EtOAc, body weight, and the blood glucose levels
were significantly reduced in mice, and the OGTT showed
that ST-EtOAc improved glucose tolerance. The serum insulin
concentration had been dramatically reduced, and the OGTT
showed the sensitivity of insulin had been improved. In the
histopathological examination, ST-EtOAc also showed significant
protection of the pancreas in KK-Ay mice. In addition, we
observed a significant decline of TG, TC, and FFA levels
in the serum of groups treated with ST-EtOAc. In another
aspect, the level of HDL-C in the serum was in a certain
degree improved in the KK-Ay mice treated with ST-EtOAc.
Levels of TG, TC, and FFA in the liver and muscles were
reduced significantly in T2DM mice treated with ST-EtOAc.
Histopathological examination of mice livers showed that
ST-EtOAc efficiently rescued liver steatosis associated with
T2DM dose-dependently. These results showed that ST-EtOAc
improved GLUT4 translocation and promoted expression level
of GLUT4, thereby lowering blood glucose levels in mice and
improving insulin resistance.
As previously reported, there are two signaling pathways
leading to GLUT4 translocation to PM (Fullerton et al.,
2012; Cazarolli et al., 2013), including the activation of PI3K
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FIGURE 8 | (A) Effects of ST-EtOAc on AMPK phosphorylation and GLUT4 expression in skeletal muscle. (B) Effects of ST-EtOAc on AMPK phosphorylation in liver.
+++P ≤ 0.001, compared to normal control; ∗∗∗P ≤ 0.001, ∗∗P ≤ 0.01, ∗P ≤ 0.05, compared to T2DM mice treated with vehicle.
and the activation of AMPK. In this study, when the L6
cells were incubated with compound C for 30 min before
addition of ST-EtOAc, the translocation of GLUT4 to PM
caused by ST-EtOAc stimulation was mainly inhibited by
the addition of compound C (Figure 2B). However, the
addition of Wortmannin had no effect on the IRAP trafficking
response (Figure 2C). These results suggested that ST-EtOAc
enhanced GLUT4 translocation by specifically targeting the
AMPK pathway.
AMPK, an enzyme that regulates the body’s balance of energy,
has been investigated as a potential therapeutic target for the
treatment of T2DM (Fullerton et al., 2012). In glucose and
lipid metabolism, the phosphorylation and activation of AMPK
leads to GLUT4 translocation and eventually glucose uptake. It
also acts primarily by directly affecting the activity of enzymes
involved in carbohydrate, lipid, and protein biosyntheses
and secondarily by long-term transcriptional control of key
components (Rana et al., 2014). In our study, we detected
the expression of p-AMPK in L6 cells and tissues using
western blotting after administration of ST-EtOAc. As the
data shown in Figures 8A,B, the content of p-AMPK in ST-
EtOAc treated groups was significantly increased compared to
the non-treated group. The result means that in vitro, ST-
EtOAc enhanced the GLUT4 translocation through upregulating
the level of p-AMPK in L6 cells. In vivo, AMPK in mouse
skeletal muscle and liver were also detected, and western
blotting data showed that the content of p-AMPK in liver
and muscle in the ST-EtOAc-treated groups was significantly
increased compared with the vehicle group. These in vitro
and in vivo results coincided with each other, proving that
ST-EtOAc upregulated contents of the p-AMPK and GLUT4,
improved glucolipid metabolism, and relieved the IR in KK-
Ay so that developing the effects on antidiabetes in vitro and
in vivo.
This study showed ST-EtOAc had promising positive
activity on GLUT4 translocation based on a cell-based GLUT4
translocation system. Further investigation in vitro and in vivo
showed that ST-EtOAc indicated a strong stimulation on GLUT4
translocation and enhanced the glucose uptake significantly.
In vitro, ST-EtOAc improved glucose tolerance, reduced
hyperglycemia and reduced insulin levels. ST-EtOAc has the
potential to treat diabetes by targeting the AMPK pathway.
Furthermore, according to the oral acute toxicity study on ST-
EtOAc, the single oral dose LD50 for KM mice was proposed to be
more than 6500 mg/kg/day. These results indicate that ST-EtOAc,
at the dosages used in our study, did not result in any side effects.
Therefore ST-EtOAc can be classified as a non-toxic substance
according to the common classification of the relative toxicity
of chemicals. In order to identify the main components from
ST-EtOAc effectively, 13 compounds had been isolated by the
off-line semipreparative HPLC–NMR. Some of these compounds
have been reported to be effective bioactive compounds, such as
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genistin, which has shown an effect on weight gain in pregnant
rats (Cao et al., 2015), and quercetin, which has shown to
stimulate insulin secretion and reduce the viability of rat INS-1
beta-cells (Kittl et al., 2016). The research suggests that ST-EtOAc
has the potential to become an effective agent in the therapy of
diabetes mellitus.
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